

Microsoft Bing

国内版 国际版

Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Oppo



ALL IMAGES VIDEOS

Add the Give

25,100 Results Any time ▾

### [Neoadjuvant therapy for resectable pancreatic ductal ...](#)

<https://pubmed.ncbi.nlm.nih.gov/32063686>

Neoadjuvant therapy is increasingly being recommended to patients with pancreatic ductal adenocarcinoma, however, patient-centered research on its use is lacking. In this review, we highlight opportunities to focus research efforts in the domains of patient preferences, patient-reported outcomes, patient experience, and survivorship.

Cited by: 2 Author: Jordan M Cloyd, Allan Tsung, John Hays, ...  
Publish Year: 2020

### [Adjuvant and neoadjuvant chemotherapy in pancreatic ...](#)

<https://journals.lww.com/jpancreatology/Fulltext/...>

Search Tools

Turn off Hover Translation (关闭取词)

Neoadjuvant chemotherapy is increasingly utilized in cases of borderline resectable or locally advanced pancreatic cancer, but there is still a lack of proof of concept studies. High-quality evidence from randomized controlled trials to identify the indications and benefits of neoadjuvant therapy in pancreatic cancer are required.

### [Adjuvant and neoadjuvant chemotherapy in pancreatic ductal ...](#)

[journals.lww.com/jpancreatology/Fulltext/2020/03000/Adjuvant\\_and\\_neoadjuv...](https://journals.lww.com/jpancreatology/Fulltext/2020/03000/Adjuvant_and_neoadjuv...)

Was this helpful?  

### [Neoadjuvant therapy for resectable pancreatic ductal ...](#)

<https://pubmed.ncbi.nlm.nih.gov/32063686>

Neoadjuvant therapy is increasingly being recommended to patients with pancreatic ductal adenocarcinoma, however, patient-centered research on its use is lacking. In this review, we highlight opportunities to focus research efforts in the domains of patient preferences, patient-reported outcomes, patient experience, and survivorship.

Cited by: 3

Author: Jordan M Cloyd, Allan Tsung, John Hays, C...

Publish Year: 2020

### [Adjuvant and neoadjuvant chemotherapy in pancreatic ductal ...](#)

<https://journals.lww.com/jpancreatology/Fulltext/...>

Neoadjuvant chemotherapy is increasingly utilized in cases of borderline resectable or locally advanced pancreatic cancer, but there is still a lack of proof of concept studies. High-quality evidence from randomized controlled trials to identify the indications and benefits of neoadjuvant therapy in pancreatic cancer are required.

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 63508

Manuscript Type: MINIREVIEWS

Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care

Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma

**Abstract**

PDAC is an aggressive malignancy that is best treated in a multidisciplinary fashion using surgery, chemotherapy, and radiation. Adjuvant chemotherapy has shown to have a significant survival benefit in patients with resected PDAC. However, up to 50% of patients fail to receive adjuvant chemotherapy due to postoperative complications, poor patient performance status or early disease progression. In order to ensure the delivery of chemotherapy, an alternative strategy is to administer systemic treatment

Match Overview

Match	Source	Words	Percentage
1	Crossref	76 words	2%
	Zachary J. Brown, Jordan M. Cloyd. "Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma"		
2	Internet	69 words	2%
	crawled on 25-Sep-2020 www.wjnet.com		
3	Internet	43 words	1%
	crawled on 23-Jul-2020 res.mdpi.com		
4	Crossref	24 words	1%
	Georgios Giannetakis, Vincent P. Groot, Alex B. Blair, Daniele I.A. Laheru et al. "Survival in Locally Advanced Pancreatic Adenocarcinoma"		
5	Crossref	23 words	1%
	Susan Tsai, Kathleen K. Christens, Ben George, Paul S. Ritchie et al. "A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy in Locally Advanced Pancreatic Adenocarcinoma"		
6	Internet	18 words	1%
	crawled on 20-Jan-2020 cdn.amegroups.cn		
7	Crossref	12 words	<1%
	Ahmed M. Amer, Mohamed Zaid, Baishali Chaudhury, Dalila Elganany et al. "Imaging-based biomarkers: Changes in the management of pancreatic ductal adenocarcinoma"		
8	Crossref	12 words	<1%
	Multimodality Management of Borderline Resectable Pancreatic Adenocarcinoma		

国内版 国际版

Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opport



ALL

IMAGES

VIDEOS

42,300 Results

Any time

### [Neoadjuvant therapy for resectable pancreatic ductal ...](#)

<https://pubmed.ncbi.nlm.nih.gov/32063686>

Neoadjuvant therapy is increasingly being recommended to patients with pancreatic ductal adenocarcinoma, however, patient-centered research on its use is lacking. In this review, we highlight opportunities to focus research efforts in the domains of patient preferences, patient-reported outcomes, patient experience, and survivorship.

Cited by: 3

Author: Jordan M Cloyd, Allan Tsung, John Hays,...

Publish Year: 2020

### [Adjuvant chemotherapy in pancreatic cancer: state of the ...](#)

<https://pubmed.ncbi.nlm.nih.gov/32541325>

Purpose of review: The modalities of management of resectable pancreatic ductal adenocarcinoma (PDAC) have evolved in recent years with new practice guidelines on adjuvant chemotherapy and results of randomized phase III trials. The aim of this review is to describe the state of the art in this setting and to highlight future possible perspectives.

Cited by: 4

Author: Léo Mas, Lilian Schwarz, Jean-Baptiste ...

Publish Year: 2020

### [Adjuvant and neoadjuvant chemotherapy in pancreatic ...](#)

<https://journals.lww.com/jpancreatology/Fulltext/...>

Neoadjuvant chemotherapy is increasingly utilized in cases of borderline resectable or locally advanced pancreatic cancer, but there is still a lack of proof of concept studies. High-quality evidence from randomized controlled trials to identify the indications and benefits of neoadjuvant therapy in pancreatic cancer are required.

### [Neoadjuvant therapy for pancreas cancer: Global ...](#)

<https://onlinelibrary.wiley.com/doi/10.1002/jso.26365>

Apr 08, 2021 - Neoadjuvant therapy for pancreas cancer: Global perspective and optimal care pathways in low to middle-income countries Senthil J. Rajappa MD, DNB, DM , Division of Medical Oncology, Basavatarakam Indo American Cancer Hospital & Research Institute, Banjara Hills, Hyderabad, Telangana, India

Author: Senthil J Rajappa, Rakesh Pinninti, C...

Publish Year: 2021